National Cancer Institute-funded Specialized Program of Research Excellence (SPORE)
1. GI SPORE
The Arizona Cancer Center is one of only five institutions nationwide to receive a GI SPORE; the others include Harvard, Johns Hopkins, the University of North Carolina, and Vanderbilt University. Originally funded in 2002, the GI SPORE was renewed in 2007 for another five years and funded at $12 million. Eugene W. Gerner, Ph.D, is the SPORE PI and the director of the Arizona Cancer Center’s Gastrointestinal (GI) Cancer Program.
The Arizona Cancer Center Lymphoma Research Consortium, in partnership with the University of Rochester James P. Wilmot Cancer Center, received a five-year, $11.5 million SPORE grant. These lead institutions will be collaborating with researchers from Virginia Commonwealth Massey Cancer Center. The highly competitive grant will fund translational research projects designed to quickly advance findings from the laboratory to clinical settings and improve care and find cures. Thomas P. Miller, MD, is co-principal investigator for the SPORE and director of the Arizona Cancer Center Lymphoma Program.
Program Project Grants
1. Prostate Carcinoma: Invasion and Metastasis Factors (5P01) CA56666-10) (P.I.: Raymond Nagle, M.D., Ph.D. & Anne Cress, Ph.D.) (runs through 2009 & under competitive renewal review) (Cancer Biology and Genetics Program)
2. Center for Gamma Ray Imaging (5P41EB002035, P.I. Harrison H. Barrett, Ph.D.) (runs through 2009 & under competitive renewal review) (Cancer Imaging Program)
3. Colon Cancer Prevention Program Project Grant (5P01 CA41108-21, P.I.: Peter Lance, M.D.) (runs through 2010) (Cancer Prevention and Control Program)
4. Chemoprevention of Skin Cancer Program Project Grant (5P01 CA 27502-28, P.I.: David S. Alberts, M.D& Tim Bowden, Ph.D.) (runs through 2009 & under competitive renewal review)(Cancer Prevention and Control Program)
5. Therapeutic Targeting of Hypoxic and Oxidative Stress (5P01 CA017094-33; P.I.: Robert Dorr, Ph.D.) (Renewed 2007) (Therapeutic Development Program)
6. Targets for Therapeutics in Pancreatic Cancer Program Project (5P01 CA109552, P.I. Daniel Von Hoff, M.D. & Robert Dorr, Ph.D. and Steve Stratton, Ph.D. –Preclinical Drug Development Core Service Leaders) (runs through 2010) (collaboration between TGEN & AZCC) (Therapeutic Development Program)